{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:09:23Z","timestamp":1783973363500,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jtha.2026.02.017","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:52:10Z","timestamp":1772610730000},"page":"1587-1592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safeguarding global anticoagulant supply and access"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4367-5182","authenticated-orcid":false,"given":"Bingwen Eugene","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques Kah Yee","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel J.","family":"Favaloro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.02.017_bib1","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(19)33135-6","article-title":"Running thin: implications of a heparin shortage","volume":"395","author":"McCarthy","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2026.02.017_bib2","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/S2352-3026(22)00171-5","article-title":"Counting the carbon cost of heparin: an evolving tragedy of the commons?","volume":"9","author":"Fan","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2026.02.017_bib3","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nbt1407","article-title":"Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events","volume":"26","author":"Guerrini","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtha.2026.02.017_bib4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1039\/b819896a","article-title":"Lessons learned from the contamination of heparin","volume":"26","author":"Liu","year":"2009","journal-title":"Nat Prod Rep"},{"key":"10.1016\/j.jtha.2026.02.017_bib5","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1634\/theoncologist.2019-0910","article-title":"When pigs fly: a multidisciplinary approach to navigating a critical heparin shortage","volume":"25","author":"Rosovsky","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jtha.2026.02.017_bib6","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/jth.14372","article-title":"Imminent risk of a global shortage of heparin caused by the African Swine Fever afflicting the Chinese pig herd","volume":"17","author":"Vilanova","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.02.017_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.mayocp.2020.10.031","article-title":"Coronavirus disease 2019-associated coagulopathy","volume":"96","author":"Lippi","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jtha.2026.02.017_bib8","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/ajh.26575","article-title":"Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: assessing the long-term outcomes in COVID-19 patients","volume":"97","author":"Fan","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2026.02.017_bib9","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/jth.14810","article-title":"ISTH interim guidance on recognition and management of coagulopathy in COVID-19","volume":"18","author":"Thachil","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.02.017_bib10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40256-021-00475-9","article-title":"Impact of the COVID-19 Pandemic on Global Anticoagulant Sales: a cross-sectional analysis across 39 countries","volume":"21","author":"Hernandez","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jtha.2026.02.017_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjph-2024-001767","article-title":"Evaluating the utilisation patterns of pharmacological therapy in COVID-19 patients: an ecological study in Italy","volume":"3","author":"Marino","year":"2025","journal-title":"BMJ Public Health"},{"key":"10.1016\/j.jtha.2026.02.017_bib13","unstructured":"Chery L, Hassani Z, Durand L, Boisseau D, Monguillon V, Grimaldi D, Taillemite S, Marie BS, Gendron N. Carbon footprint of direct oral anticoagulants in atrial fibrillation and venous thromboembolism. Haematologica. In press."},{"key":"10.1016\/j.jtha.2026.02.017_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ocecoaman.2021.105660","article-title":"The effect of COVID-19 pandemic on port performance: Evidence from China","volume":"209","author":"Xu","year":"2021","journal-title":"Ocean Coast Manag"},{"key":"10.1016\/j.jtha.2026.02.017_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1115650","article-title":"Impact of the COVID-19 epidemic on medical product imports from China from outbreak to stabilization: monthly panel data regression and instrumental variable test","volume":"11","author":"Pu","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.jtha.2026.02.017_bib16","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/ajhp\/zxac381","article-title":"Changes in anticoagulant and antiplatelet drug supply at US hospitals before and during the COVID-19 pandemic (2018-2021)","volume":"80","author":"Wong","year":"2023","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jtha.2026.02.017_bib17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.coph.2011.12.002","article-title":"Synthetic heparin","volume":"12","author":"Linhardt","year":"2012","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jtha.2026.02.017_bib18","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2315586121","article-title":"Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin","volume":"121","author":"Douaisi","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2026.02.017_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbapap.2019.140301","article-title":"Chemoenzymatic synthesis of ultralow and low-molecular weight heparins","volume":"1868","author":"Wang","year":"2020","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"key":"10.1016\/j.jtha.2026.02.017_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ymben.2022.01.002","article-title":"Multiplex genome editing of mammalian cells for producing recombinant heparin","volume":"70","author":"Thacker","year":"2022","journal-title":"Metabc Eng"},{"key":"10.1016\/j.jtha.2026.02.017_bib21","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/jth.14975","article-title":"Coagulopathy in COVID-19","volume":"18","author":"Iba","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.02.017_bib22","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.3390\/jcm14082591","article-title":"Oral anticoagulation therapy: an update on usage and costs in the endemic COVID-19 era","volume":"14","author":"Favaloro","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtha.2026.02.017_bib23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1055\/a-2667-6770","article-title":"COVID-19 and anticoagulant use: did the pandemic push DOACs ahead of warfarin?","volume":"52","author":"Fan","year":"2026","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jtha.2026.02.017_bib25","series-title":"WHO Model List of Essential Medicines, 22nd List","year":"2021"},{"key":"10.1016\/j.jtha.2026.02.017_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-49606-z","article-title":"Digitalization enhancement in the pharmaceutical supply network using a supply chain risk management approach","volume":"13","author":"Wong","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtha.2026.02.017_bib27","article-title":"The impact of smart pump technology in the healthcare system: a scope review","volume":"15","author":"Alamer","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jtha.2026.02.017_bib28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2471\/BLT.21.287516","article-title":"COVAX and equitable access to COVID-19 vaccines","volume":"100","author":"Yoo","year":"2022","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jtha.2026.02.017_bib29","doi-asserted-by":"crossref","first-page":"e918","DOI":"10.1016\/S2352-3026(25)00204-2","article-title":"Sustainable anticoagulation for climate resilient care","volume":"12","author":"Fan","year":"2025","journal-title":"Lancet Haematol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626001340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626001340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:59:15Z","timestamp":1783972755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626001340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1538783626001340"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.02.017","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safeguarding global anticoagulant supply and access","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}